• Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022

    4 days ago - By Precision Biosciences

    DURHAM, N.C. --Aug. 1, 2022- Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022
    Read more ...